Zoetis Inc. (NYSE:ZTS) Receives $221.44 Average Target Price from Brokerages

Shares of Zoetis Inc. (NYSE:ZTS) have been given an average rating of “Buy” by the ten brokerages that are presently covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $221.44.

ZTS has been the subject of several recent analyst reports. BTIG Research lifted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler boosted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus boosted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th.

Zoetis Price Performance

ZTS opened at $176.74 on Monday. The stock’s 50 day moving average price is $184.51 and its 200-day moving average price is $180.81. Zoetis has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market capitalization of $79.74 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 2.74 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the firm posted $1.36 earnings per share. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. On average, equities research analysts predict that Zoetis will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s dividend payout ratio is currently 32.33%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Peapack Gladstone Financial Corp lifted its holdings in shares of Zoetis by 1.8% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 77,004 shares of the company’s stock worth $15,045,000 after acquiring an additional 1,393 shares during the last quarter. Tidal Investments LLC lifted its stake in shares of Zoetis by 3.4% during the 3rd quarter. Tidal Investments LLC now owns 15,210 shares of the company’s stock worth $2,972,000 after acquiring an additional 500 shares during the last quarter. Destination Wealth Management boosted its holdings in Zoetis by 0.8% during the 3rd quarter. Destination Wealth Management now owns 123,844 shares of the company’s stock valued at $24,197,000 after acquiring an additional 1,027 shares during the period. Wilmington Savings Fund Society FSB boosted its stake in shares of Zoetis by 801.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 18,606 shares of the company’s stock valued at $3,635,000 after purchasing an additional 16,541 shares during the period. Finally, World Investment Advisors LLC grew its holdings in shares of Zoetis by 29.1% in the third quarter. World Investment Advisors LLC now owns 34,236 shares of the company’s stock worth $6,689,000 after purchasing an additional 7,709 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.